Home > Signaling Pathways>Immunology/Inflammation>NLRP3>CY 09
CY 09

This product is for research use only, not for human use. We do not sell to patients.

CY 09
For small sizes, please check our retail website as below: www.invivochem.com
Size Price Stock
100mg$775Check With Us
200mg$1160Check With Us
500mg$1740Check With Us
email: [email protected]        [email protected]

Cat #: V18919 CAS #: 1073612-91-5 Purity ≥ 98%

Description: CY 09 is a novel, potent, selective and direct NLRP3 inhibitor that blocks NLRP3 inflammasome assembly and activation, and exhibits therapeutic effects on mouse models of cryopyrin-associated autoinflammatory syndrome (CAPS) and type 2 diabetes.

References: Jiang H, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017 Nov 6;214(11):3219-3238.

Top Publications Citing Invivochem Products
Product Catalog 2022
Bulletin Board
Guide to Product Handling
Publications Citing InvivoChem Products
Product Promise
Promise
Molecular Weight (MW)423.43
Molecular FormulaC19H12F3NO3S2
CAS No.1073612-91-5
SMILES CodeO=C(O)C1=CC=C(/C=C(SC(N2CC3=CC=CC(C(F)(F)F)=C3)=S)C2=O)C=C1 
SynonymsCY 09; CY-09; CY09
ProtocolIn VitroCY-09 exhibits a dose-dependent inhibitory effect on monosodium urate (MSU), nigericin, ATP-induced caspase-1 activation and IL-1β secretion at the doses of 1 to10 µM in LPS-primed bone marrow-derived macrophages (BMDMs). Cytosolic LPS-induced noncanonical NLRP3 activation in BMDMs can also be blocked by CY-09 treatment. CY-09 specifically inhibits NLRP3 inflammasome activation and has no effect on LPS-induced priming effects. CY-09 treatment remarkably suppresses nigericin-induced ASC oligomerization. It is found that CY-09 treatment inhibits the interaction of Flag-NLRP3 and mCherry-NLRP3 in HEK-293T cells, suggesting that CY-09 blocks NLRP3 oligomerization.
In VivoCY-09 treatment in vivo efficiently suppresses monosodium urate (MSU) injection-induced IL-1β production and neutrophil influx, suggesting that CY-09 can block MSU-induced NLRP3 inflammasome activation in vivo. CY-09 treatment also increases the survival of NLRP3 mutant mice up to days 30 to 48 even after treatment is stopped at day 25. The caspase-1 cleavage observed in adipose tissue of high-fat diet (HFD)-treated mice is also suppressed by CY-09.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Preparing Stock Solutions
Solvent volume to be added Mass (the weight of a compound)
Mother liquor concentration 1mg5mg10mg20mg
1mM2.3617 mL11.8083 mL23.6167 mL47.2333 mL
5mM0.4723 mL2.3617 mL4.7233 mL9.4467 mL
10mM0.2362 mL1.1808 mL2.3617 mL4.7233 mL
20mM0.1181 mL0.5904 mL1.1808 mL2.3617 mL
Quality Control Documentation
The molarity calculator equation
Mass(g) = Concentration(mol/L) × Volume(L) × Molecular Weight(g/mol)
Mass
 
=
Concentration
 
×
Volume
 
×
Molecular Weight*
The dilution calculator equation
Concentration(start) × Volume(start) = Concentration(final) × Volume(final)

This equation is commonly abbreviated as: C1 V1 = C2 V2

Concentration(start)
C1
 
×
 
Volume(start)
V1
 
=
 
Concentration(final)
C2
 
×
 
Volume(final)
V2
Step One: Enter information below
Dosage mg/kg Average weight of animals g Dosing volume per animal µL Number of animals
Step Two: Enter the in vivo formulation
%DMSO + % + %Tween 80 + %ddH2O
Calculation Results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in µL DMSO(Master liquid concentration mg/mL) ,Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation: Take µL DMSO master liquid, next add µL PEG300, mix and clarify, next add µL Tween 80,mix and clarify, next add µL ddH2O,mix and clarify.
Note:
  • (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
  • (2) Be sure to add the solvent(s) in order.